Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q3 2023 13F Holders as of 30 Sep 2023
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 112,423,967
- Total 13F value
- $122,551,525
- Share change
- -171,570
- Put/Call ratio
- 169%
- SEC-reported price per share
- $1.09
- Number of holders
- 91
- Value change
- -$3,809,593
- Number of buys
- 36
- Number of sells
- 40
- Shares outstanding
- 94,372,096
Holder snapshot
7 facts
Show 1 more fact
Security identity
1 fact
Report period
Q3 2023
Institutions
91
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2023
Previous quarter: Q2 2023
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
30 Jun 2023
13F
Lead comparable stake: 17%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 17%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
17%
NEA Management Company, LLC
16%
BlackRock Finance, Inc.
9.6%
VANGUARD GROUP INC
8.3%
ORBIMED ADVISORS LLC
7.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
17%
|
$30,963,541
15,960,588 shares
|
— | 30 Jun 2023 |
| NEA Management Company, LLC |
13F
Company
|
16%
|
$29,074,378
14,986,793 shares
|
— | 30 Jun 2023 |
| BlackRock Finance, Inc. |
13F
Company
|
9.6%
|
$17,644,831
9,095,274 shares
|
— | 30 Jun 2023 |
| VANGUARD GROUP INC |
13F
Company
|
8.3%
|
$15,107,052
7,787,140 shares
|
— | 30 Jun 2023 |
| ORBIMED ADVISORS LLC |
13F
Company
|
7.6%
|
$13,839,019
7,133,515 shares
|
— | 30 Jun 2023 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
5.8%
|
$10,576,124
5,451,610 shares
|
— | 30 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
91
Shares
112,423,967
Rows available
91
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
96
Q3 2023 holders
91
Holder diff
-5
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 value | Q3 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend